Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive multiarm immunotherapy trial for moderate COVID-19
2020-001854-23Phase 2Terminated
- Sponsor
- Società Italiana Malattie Infettive e Tropicali
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydroxychloroquine, tocilizumab, sarilumab, siltuximab, canakinumab and 2 more in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Società Italiana Malattie Infettive e Tropicali. Started Jun 2020; status: terminated.
02
Drugs
hydroxychloroquinetocilizumabsarilumabsiltuximabcanakinumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001854-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001854-23.